Skip to content

Oruka Therapeutics, Inc. ORKA Professional Service Fees Payable

Professional Service Fees Payable at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s professional service fees payable?
Oruka Therapeutics, Inc. (ORKA) reported professional service fees payable of $775K in Q1 2026.
How has Oruka Therapeutics, Inc.'s professional service fees payable changed year-over-year?
Oruka Therapeutics, Inc.'s professional service fees payable increased by 59.1% year-over-year, from $487K to $775K.
What does professional service fees payable mean?
This represents the outstanding balance owed to third-party consultants, legal counsel, or other professional service providers for services rendered. It reflects the company's reliance on external expertise and the short-term cash outflows required to settle these operational obligations.